Table 3.
Combination therapy of KRAS (G12C) inhibitors in clinical trials
| ClinicalTrials.gov registration | Drug | Disease setting | Study phase | Recruitment status |
|---|---|---|---|---|
| Combined with chemotherapy | ||||
| NCT04303780 | AMG510 Docetaxel | NSCLC | III | Recruiting |
| NCT04185883 | AMG510 Docetaxel | Advanced NSCLC | I b | Recruiting |
| NCT04165031 | LY3499446 Docetaxel | Solid tumours | I/II | Terminated |
| NCT04685135 | MRTX849 Docetaxel | Metastatic NSCLC | III | Recruiting |
| Combined with targeted therapy | ||||
| NCT04185883 | AMG510 Erlotinib | Solid tumours | I b | Recruiting |
| NCT04185883 | AMG510 TNO155 | Solid tumours | I b | Recruiting |
| NCT04185883 | AMG510 Selumetinib | Solid tumours | I b | Recruiting |
| NCT04185883 | AMG510 Everolimus | Solid tumours | I b | Recruiting |
| NCT03785249 | MRTX849 Afatinib | NSCLC | I/II | Recruiting |
| NCT03785249 | MRTX849 Cetuximab | Solid tumours | I/II | Recruiting |
| NCT04793958 | MRTX849 Cetuximab | Metastatic CRC | III | Recruiting |
| NCT04330664 | MRTX849 TNO155 | NSCLC | I/II | Recruiting |
| NCT04165031 | LY3499446 Abemaciclib | Advanced NSCLC | I/II | Terminated |
| NCT04165031 | LY3499446 Erlotinib | Advanced NSCLC | I/II | Active not recruiting |
| NCT04449874 | GDC-6036 Erlotinib | Solid tumours | I a/I b | Recruiting |
| NCT04449874 | GDC-6036 Cetuximab | Solid tumours | I a/I b | Recruiting |
| NCT04449874 | GDC-6036 Bevacizumab | Solid tumours | I a/I b | Recruiting |
| Combined with immune therapy | ||||
| NCT03600883 | AMG510 Pembrolizumab | NSCLC | II | Recruiting |
| NCT03600883 | AMG510 Atezolizumab | NSCLC | II | Recruiting |
| NCT03785249 | MRTX849 Pembrolizumab | NSCLC | I/II | Recruiting |
| NCT04613596 | MRTX849 Pembrolizumab | NSCLC | II | Not yet recruiting |
| NCT04449874 | GDC-6036 Atezolizumab | Solid tumours | I a/I b | Recruiting |
NSCLC: nonsmall-cell lung cancer; CRC: colorectal adenocarcinoma. Data from ClinicalTrial.gov, accessed September 18, 2021